Research programme: metabolic disorders therapy - Alexion

Drug Profile

Research programme: metabolic disorders therapy - Alexion

Alternative Names: ENPP-1; Genn Biologics; SBC-104; SBC-105; SBC-106; SBC-342

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synageva BioPharma
  • Developer Alexion Pharmaceuticals
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Calcinosis; Metabolic disorders

Most Recent Events

  • 27 Jul 2017 Discontinued - Preclinical for Calcinosis in USA (Parenteral) as a result of Alexion's redefined R&D strategy
  • 27 Jul 2017 Discontinued - Preclinical for Metabolic disorders in USA as a result of Alexion's redefined R&D strategy
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top